Previous close | 1.8000 |
Open | 1.8000 |
Bid | 0.4000 |
Ask | 4.8000 |
Strike | 22.50 |
Expiry date | 2024-12-20 |
Day's range | 1.8000 - 1.8000 |
Contract range | N/A |
Volume | |
Open interest | 6 |
On June 20, 2024, Jon Congleton, CEO of Mineralys Therapeutics Inc (NASDAQ:MLYS), executed a significant transaction by selling 49,313 shares of the company. Following this sale, the insider now owns 926,958 shares of Mineralys Therapeutics Inc. Mineralys Therapeutics Inc is focused on developing targeted therapies for cardiovascular and kidney diseases.
On June 14, 2024, Jon Congleton, CEO of Mineralys Therapeutics Inc (NASDAQ:MLYS), executed a sale of 72,797 shares of the company, according to the SEC Filing.
Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that Alexander M. Gold, M.D. has been appointed to the Company's Board of Directors (the Board), effective June 13, 2024. “We are delighte